SOTIO Biotech
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, SOTIO Biotech sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
SOTIO Biotech: 3 sponsored US clinical trials, 1 recruiting.
SOTIO Biotech sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Squamous Cell Carcinoma of the Lung, with 1 trials.
Upper-quartile sponsor footprint
SOTIO Biotech sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
NCT06163391
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
NCT05120271
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
NCT05256381
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
NCT04234113
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
What is open in the SOTIO Biotech pipeline
1 recruiting of 3 indexed (33% open).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Squamous Cell Carcinoma of the Lung (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
SOTIO Biotech: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
SOTIO Biotech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this SOTIO Biotech page
3 registered trials is a research-attention snapshot, not an endorsement of SOTIO Biotech or any single study.
- 1 of SOTIO Biotech's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Squamous Cell Carcinoma of the Lung is the condition SOTIO Biotech studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Squamous Cell Carcinoma of the Lung trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
SOTIO Biotech pipeline card: 3 registered trials from official public datasets.Report a data error.